12 unknown. 12 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 12 |
| Phase 3 | 4 | Unknown 4 |
| Phase 1 | 3 | Unknown 3 |
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 Tirzepatide - Wolfram Syndrome | Phase 2 | Unknown | Ospedale San Raffaele | 10 | 2024-01-01 | 2024-02-22 |
| Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss. Platelet Rich Plasma, local anesthesia in external auditory canal, Intratympanic Injection - Hearing Loss, Sudden, Hearing Loss, Sensorineural | Phase 2 / Phase 3 | Unknown | Assiut University | 23 | 2023-06-01 | 2023-04-19 |
| The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss Topiramate, Systemic Steroids - Sudden Deafness, Sudden Sensorineural Hearing Loss | Phase 2 | Unknown | Chang Gung Memorial Hospital | 140 | 2022-10-17 | 2024-02-16 |
| Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome Depakine - Wolfram Syndrome | Phase 2 | Unknown | Centre d'Etude des Cellules Souches | 23 | 2021-11-26 | 2023-11-28 |
| Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. N-Acetyl Cysteine - Ototoxic Hearing Loss | Phase 1 / Phase 2 | Unknown | Sunnybrook Health Sciences Centre | 80 | 2020-02-26 | 2023-09-06 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| Latanoprost for the Treatment of Menière's Disease Latanoprost, Placebo - Menière's Disease | Phase 2 | Unknown | Synphora AB | 100 | 2013-10-01 | 2016-03-23 |
| Effectiveness of P02 Digital Hearing Aids Hearing Aids Evaluation - Hearing Loss, Bilateral, Sensorineural Hearing Loss | Phase 1 / Phase 2 | Unknown | Khon Kaen University | 100 | 2012-10-01 | 2014-04-21 |
| Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) Antioxidants, Cholesterol - Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy | Phase 2 | Unknown | University of Colorado, Denver | 100 | 2008-12-01 | 2024-05-08 |
| Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity Ringer's Lactate (0.03% Ciprofloxacin) - Hearing Loss | Phase 1 / Phase 2 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 20 | 2008-04-01 | 2010-04-22 |
| Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation Proton pump inhibitor - Hearing Loss | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 120 | 2006-08-01 | 2008-11-11 |
| Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss bed rest, prednisone - oral corticosteroid 1mg/kg/D for 1 week - Sudden Loss of Hearing | Phase 2 / Phase 3 | Unknown | Sheba Medical Center | 60 | 2006-06-01 | 2006-12-27 |
Hearing Loss, Sensorineural (4) · Hearing Loss, Sudden (3) · Diabetes Mellitus (2) · Wolfram Syndrome (2) · Cone-Rod Dystrophies (1) · Deafness (1) · Ear Diseases (1) · Hearing Loss, Bilateral (1) · Iron Metabolism Disorders (1) · Migraine Disorders (1) · Optic Atrophy (1) · Ototoxicity (1) · Peptic Ulcer (1) · Smith-Lemli-Opitz Syndrome (1)
Hearing Disorders (12) · Nervous System Diseases (12) · Neurologic Manifestations (12) · Otorhinolaryngologic Diseases (12) · Sensation Disorders (12) · Ear Diseases (11) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Eye Diseases (4) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Abnormalities, Multiple (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
Acetylcysteine (2) · Anesthesia, Local (1) · Antioxidants (1) · Bed Rest (1) · Cholesterol (1) · Ciprofloxacin (1) · Deferiprone (1) · Eggs (1) · Fumigant 93 (1) · Injection, Intratympanic (1) · Lansoprazole (1) · Latanoprost (1) · Metformin (1) · Proton Pump Inhibitors (1) · Ringer's Lactate (1)
Assiut University (1) · Centre d'Etude des Cellules Souches (1) · Chang Gung Memorial Hospital (1) · Hadassah Medical Organization (1) · Khon Kaen University (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · National Taiwan University Hospital (1) · Ospedale San Raffaele (1) · Sheba Medical Center (1) · Sunnybrook Health Sciences Centre (1) · Synphora AB (1) · University of Colorado, Denver (1)
Canada (2) · Israel (2) · Taiwan (2) · Egypt (1) · France (1) · Italy (1) · Spain (1) · Sweden (1) · Thailand (1) · United States (1)
Chen-Chi Wu, MD (1) · Chuan-Jen Hsu, MD (1) · David Zangen, Professor (1) · Eldar Carmel, MD (1) · Ellen R Elias, MD (1) · Kwanchanok Yimtae, MD (1) · Lorenzo Piemonti, MD (1) · Mikael Karlberg, MD, PhD (1) · Sam J Daniel, MD (1) · Trung N Le (1)